When did Insmed report Q2 2025 earnings?

Insmed (INSM) reported Q2 2025 earnings on August 7, 2025 before market open.

What were Insmed's Q2 2025 revenue and EPS?

Insmed reported revenue of $107.4M and diluted EPS of $-1.70 for Q2 2025.

Did Insmed beat estimates in Q2 2025?

Revenue beat the consensus estimate of $104.1M by $3.3M. EPS missed the consensus estimate of $-1.30 by $0.40.

How did Insmed's Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 18.9% from $90.3M a year earlier and diluted EPS grew 12.4% from $-1.94.

Where can I find Insmed's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0001104506-25-000043) directly on SEC EDGAR. The filing index links above go to sec.gov.

Insmed INSM Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$107.4MBeat by $3.3M Diluted EPS-$1.70Miss by $0.40

Revenue estimate$104.1M

EPS estimate-$1.30

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$390.1M

EPS estimate-$0.75

Financials

Q2 2025

Income statement

See full

Revenue$107.4M+18.9%

Gross profit$79.3M+14.4%

Operating income-$312.9M-8.3%

Net income-$321.7M-7.0%

EPS (diluted)-$1.70+12.4%

Balance sheet

See full

Cash & equivalents$1.3B+3.0%

Total debt$575.5M-52.7%

Total equity$1.2B+3,119%

Total assets$2.5B+37.0%

Cash flow

See full

Operating cash flow-$205.6M-67.2%

CapEx$3.5M-48.6%

Free cash flow-$209.1M-61.1%

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$20.12B+102%

Enterprise value$19.41B+95.7%

P/S50.5×+20.3×

Profitability

See full

Gross margin75.7%-1.9pp

Operating margin-252.4%+25.2pp

Net margin-259.8%+17.7pp

FCF margin-218.2%+59.4pp

Returns & leverage

See full

Return on equity-160.5%—

Debt / equity0.5×-30.9×

Current ratio6.7×+4.0×

Segments

By product

See full

ARIKAYCE external R&D expenses$107.4M—

Versus estimates

Revenue

Q1 2026$306.0MBeat by $5.2M Q4 2025$263.8MBeat by $32.6M Q3 2025$142.3MBeat by $26.9M

Q2 2025$107.4MBeat by $3.3M

Q1 2025$92.8MBeat by $1.4M Q4 2024$104.4MBeat by $2.4M

Diluted EPS

Q1 2026-$0.76Beat by $0.14 Q4 2025-$1.54Miss by $0.47 Q3 2025-$1.75Miss by $0.42

Q2 2025-$1.70Miss by $0.40

Q1 2025-$1.42Miss by $0.08 Q4 2024-$1.32Miss by $0.15

Ask the moment Insmed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Insmed report Q2 2025 earnings?: Insmed (INSM) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Insmed's Q2 2025 revenue and EPS?: Insmed reported revenue of $107.4M and diluted EPS of $-1.70 for Q2 2025.
Did Insmed beat estimates in Q2 2025?: Revenue beat the consensus estimate of $104.1M by $3.3M. EPS missed the consensus estimate of $-1.30 by $0.40.
How did Insmed's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 18.9% from $90.3M a year earlier and diluted EPS grew 12.4% from $-1.94.
Where can I find Insmed's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001104506-25-000043) directly on SEC EDGAR. The filing index links above go to sec.gov.